2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Blood Banking, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Women’s Health, Workforce, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Thromboembolism, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Paroxysmal Nocturnal Hemoglobinuria, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric
PAPER

2567 Systematic integration of enriched surface proteomics with transcriptomics identifies novel targets in AML

Benson M. George, MD, PhD, Anna Rodriguez Pohnlein2, Donavelle Jace Y De Castro3, Marion Abeja4, Ryan James Lumpkin5, Benyu Zhou6, Rebecca J Metivier7, Anna M Schmocker8, Katherine Donovan9, Wencke Walter, PhD10, Torsten Haferlach, MD, PhD11, Kimberly Stegmaier, MD12, Eric S Fischer, PhD13, Franziska Wachter, MD14, Ryan A. Flynn, MD, PhD15
1 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, United States
2 Cancer Biology, Dana-Farber Cancer Institute, BCMP, Harvard Medical School, Boston, United States
3 Cancer Biology, Dana-Farber Cancer Institute, BCMP, Harvard Medical School, Boston, United States
4 Cancer Biology, Dana-Farber Cancer Institute, BCMP, Harvard Medical School, Boston, United States
5 Cancer Biology, Dana-Farber Cancer Institute, BCMP, Harvard Medical School, Boston, United States
6 Broad Institute at Harvard and MIT, Boston, United States, Cancer Biology, Dana-Farber Cancer Institute, BCMP, Harvard Medical School, Boston, United States
7 Cancer Biology, Dana-Farber Cancer Institute, BCMP, Harvard Medical School, Boston, United States
8 Cancer Biology, Dana-Farber Cancer Institute, BCMP, Harvard Medical School, Boston, United States
9 Cancer Biology, Dana-Farber Cancer Institute, BCMP, Harvard Medical School, Boston, United States
10 MLL Munich Leukemia Laboratory, Munich, Germany
11 MLL Munich Leukemia Laboratory, Munich, Germany
12 Broad Institute at Harvard and MIT, Boston, United States, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, United States
13 Cancer Biology, Dana-Farber Cancer Institute, BCMP, Harvard Medical School, Boston, United States
14 Cancer Biology, Dana-Farber Cancer Institute, BCMP, Harvard Medical School, Boston, United States, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, United States
15 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, Boston, United States

Background: Cell surface proteins are attractive targets for novel immuno- and cellular therapies. However, RNA abundance does not reliably predict protein abundance at the cell surface, and whole-proteome profiling may fail to detect low-abundance or selectively surface-enriched proteins. This creates a critical gap in target discovery, particularly for pediatric AML, where lineage- and subtype-specific surface vulnerabilities remain incompletely defined.

 

Methods: We performed surface-enriched proteomic profiling of 25 leukemia cell lines using membrane-impermeable Sulfo-NHS-SS-Biotin labeling of exposed cell-surface lysines followed by streptavidin affinity enrichment and mass spectrometry. Surface-proteomic data were integrated with matched whole-proteome and transcriptomic datasets. Candidate proteins were annotated using surface protein classification scores, assessed for enrichment in the surface fraction, and evaluated for RNA–protein concordance. CD70 was examined as an exemplar target and orthogonally validated in primary patient samples.

 

Result: To determine the depth and specificity of direct surface-proteomic profiling, we first compared protein detection across matched whole-cell and surface datasets and assessed proteins by surface protein classification score. Surface proteomics identified a more restricted protein set (682 unique proteins/cell-line) than whole-cell proteomics (5,009 proteins/cell-line) and was enriched for proteins with predicted surface localization, supporting successful enrichment of the surfaceome. Importantly, surface profiling detected proteins not identified in matched whole-cell datasets, demonstrating that direct surface capture can reveal candidate targets missed by whole-cell proteomic approaches.

 

To determine whether transcriptomic data could serve as a surrogate for protein-level target discovery, we integrated proteomic measurements with CCLE RNA-sequencing data and quantified RNA-protein concordance. Mass spectrometry-detected proteins generally had higher RNA expression (42 TPM) than proteins detected only at the transcript level (8 TPM). We modeled the probability of detection by mass-spectrometry based on RNA-sequencing output and found that a TPM of 26 translated to a 50% likelihood of identifying a protein by mass-spectrometry. Across, all cell lines, we found that an average of 4955 genes were detected in both the RNA-sequencing and mass spectrometry approaches. There was an average of 108 genes found by proteomics only and 6838 genes found by RNA-sequencing only. RNA-protein correlation was modest (R²=0.349). 173 protein-enriched and 135 RNA-enriched genes were discordant. These findings indicate that RNA expression is a sensitive initial screening layer but is insufficient to reliably predict protein abundance or nominate surface-accessible therapeutic targets.

 

We then compared KMT2A-rearranged and KMT2A-wild-type myeloid cell lines across whole-cell proteomic, surface-proteomic, and transcriptomic datasets. CD70 emerged as a particularly compelling candidate, with enrichment in the surface-proteomic dataset and concordant RNA expression in KMT2A-rearranged AML. Analysis of a Munich Leukemia Laboratory patient cohort independently confirmed CD70 enrichment in KMT2A-rearranged AML.

 

Finally, to investigate whether direct surface capture identifies biologically relevant proteins outside conventional surface annotations, we characterized proteins with a surface prediction score of zero. These noncanonical surface-captured proteins included a substantial subset of RNA-binding proteins, with recurrent representation across myeloid cell lines. Surface-captured RNA-binding proteins differed from whole-cell-only RNA-binding proteins in annotated function or post-translational features. These findings suggest that the surface-accessible proteome includes noncanonical protein classes that would not be prioritized using standard surface annotations or transcript-based approaches alone.

 

Conclusion: Direct surface proteomics enriches the AML surfaceome and identifies candidate therapeutic targets that may be missed by whole-proteome or transcriptomic profiling. Although RNA expression is useful as a sensitive screening tool, it does not reliably predict surface protein abundance. Our work highlights how integrating surface proteomics with transcriptomic and orthogonal clinical validation datasets can improve therapeutic target nomination in AML.

Franziska Wachter, MD: No relevant conflicts of interest to declare.